|Bid||19.15 x 1000|
|Ask||19.98 x 1400|
|Day's Range||19.10 - 19.69|
|52 Week Range||9.68 - 19.95|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 26, 2018 - Mar 2, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||21.10|
Twenty-one analysts are tracking Alexion Pharmaceuticals in December 2017. Six of them are recommending a “strong buy,” while 12 are recommending a “buy.”
Investors in Halozyme Therapeutics (HALO) need to pay close attention to the stock based on moves in the options market lately.
NEW YORK, NY / ACCESSWIRE / December 8, 2017 / Halozyme Therapuetics and XOMA Corporation both hit brand new highs during intra-day trading yesterday. Halozyme announced a collaboration and license agreement ...
The Cambridge, Mass.-based firm unveiled positive top-line results from its Phase 2 study of SAGE-217 in patients with moderate to severe major depressive disorder.
Alexion Pharmaceuticals, Inc. and Halozyme Therapeutics, Inc. announced today a collaboration and license agreement that enables Alexion to use Halozyme’s ENHANZE® drug-delivery technology in the development of subcutaneous formulations for their portfolio of products.
U.S. stocks were mixed on Wednesday with the S&P 500 and Dow Jones Industrial Average both dipping, while the Nasdaq Composite advanced slightly in a quiet session the day before Thanksgiving. Asian markets ...
NEW YORK, NY / ACCESSWIRE / November 21, 2017 / Shares of Halozyme and Acorda both closed in the green on Monday with Acorda closing up almost 10% after announcing it would discontinue a Parkinson's therapy ...
SAN DIEGO , Nov. 15, 2017 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies will participate in two upcoming investor ...
NEW YORK, Nov. 14, 2017-- In a release issued under the same headline on November 13th, 2017 by Fundamental Markets, please note that in the P ure Storage's Recent Financial Performance section, the first ...
NEW YORK, Nov. 13, 2017-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Pure ...
SAN DIEGO , Nov. 10, 2017 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that it will present nonclinical data at the 32 nd Annual Meeting of the Society for Immunotherapy of ...
-- Strong ENHANZE® Momentum Following Landmark Collaboration Agreement with Bristol-Myers Squibb -- -- Royalty Revenue Increased 31 Percent from Prior-Year Period to $17.1 million on Growing Sales of Herceptin ...
NEW YORK, NY / ACCESSWIRE / November 7, 2017 / Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will be discussing their earnings results in their Q3 Earnings Call to be held on November 7, 2017 at 4:30 PM ...
Halozyme Therapeutics (HALO) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.
Over the last month, growth of ETFs holding HALO is favorable, with net inflows of $4.82 billion. This is among the highest net inflows seen over the last one-year and the rate of additional inflows appears to be increasing.
SAN DIEGO, Oct. 31, 2017 /PRNewswire/ -- Halozyme Therapeutics, Inc. (HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced that Janssen Biotech, Inc. has initiated the first of three planned Phase 3 clinical trials evaluating a subcutaneous (SC) delivery of Darzalex® (daratumumab) with Halozyme's proprietary ENHANZE® technology. The initial Phase 3 study is in amyloidosis patients, with additional Phase 3 studies in multiple myeloma and smoldering myeloma patients planned for near-term initiation. The subcutaneous formulation of daratumumab has an estimated administration time of approximately 5 minutes compared to the multi-hour intravenous infusion, potentially offering new benefits to patients, caregivers and health systems.
NEW YORK, NY / ACCESSWIRE / October 31, 2017 / Shares of both Teva Pharmaceuticals and Halozyme Therapeutics closed higher on Monday. Teva announced a new Chief Executive. While Halozyme didn't have any ...
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Halozyme Therapeutics, Inc. Here are 5 ETFs with the largest exposure to HALO-US. Comparing the performance and risk of Halozyme Therapeutics, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)